Global Pulmonary Renal Syndrome Treatment Market to Witness Significant Revenue Growth Through 2028
Verfasser: yogesh on Wednesday, 6 March 2019Pulmonary renal syndrome is the occurrence of renal failure which is associated with respiratory failure. Pulmonary renal syndrome can lead to mortality if not treated properly. Some of the common causes of are autoimmune diseases such as granulomatosis with polyangiitis, antiglomular basement membrane antibodies disease and many more. In autoimmune disorders, the immune system attacks the person’s own body. Pulmonary renal syndrome shows symptoms of Pulmonary Renal Syndrome are cough, fever, Hematuria, Dyspnea etc. The treatment of Pulmonary Renal Syndrome can be done using medications which include corticosteroids and immunosuppressive medicines. Corticosteroids are the drugs that work like cortisol, which is produced naturally in the body. These medications are responsible for reducing inflammation. Apart from Pulmonary Renal Syndrome, corticosteroids have been used for many other diseases such as arthritis, asthma and other skin problems. These can be taken orally or in the form of injections. Corticosteroids are not so expensive, hence, they are expected to increase the revenue share in the pulmonary renal syndrome treatment market.